Lasse Saarimäki1, Jonas Hugosson2, Teuvo L Tammela3, Sigrid Carlsson4, Kirsi Talala5, Anssi Auvinen6. 1. University of Tampere, School of Medicine, Tampere, Finland. Electronic address: Lasse.saarimaki@fimnet.fi. 2. Department of Urology, Sahlgrenska University Hospital, Göteborg, Sweden; Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Sweden. 3. University of Tampere, School of Medicine, Tampere, Finland; Department of Urology, Tampere University Hospital, Tampere, Finland. 4. Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Sweden; Urology Service at the Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA. 5. Finnish Cancer Registry, Helsinki, Finland. 6. University of Tampere, School of Health Sciences, Tampere, Finland.
Abstract
BACKGROUND: The European Randomised Study of Screening for Prostate Cancer trial has shown a 21% reduction in prostate cancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr interval and higher PSA cut-off. OBJECTIVE: To evaluate the impact of screening interval and PSA cut-off on PC detection and mortality. DESIGN, SETTING, AND PARTICIPANTS: We analysed the core age groups (55-69 yr at entry) of the Finnish (N=31 866) and Swedish (N=5901) screening arms at 13 yr and 16 yr of follow-up. Sweden used a screening interval of 2 yr and a PSA cut-off of 3.0ng/ml, while in Finland the screening interval was 4 yr and the PSA cut-off 4.0ng/ml (or PSA 3.0-3.9ng/ml with free PSA<16%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We compared PC detection rate and PC mortality between the Finnish and Swedish centres and estimated the impact of different screening protocols. RESULTS AND LIMITATIONS: If the Swedish screening protocol had been followed in Finland, 122 additional PC cases would have been diagnosed at screening, 84% of which would have been low-risk cancers, and four leading to PC death. In contrast, if a lower PSA threshold had been applied in Finland, at least 127 additional PC would have been found, with 19 PC deaths. CONCLUSIONS: The small number of deaths among cases that would have been potentially detectable in Finland with the Swedish protocol (or those that would have been missed in Sweden with the Finnish approach) is unlikely to explain the differences in mortality in this long of a follow-up. PATIENT SUMMARY: A prostate-specific antigen threshold of 3ng/ml versus 4ng/ml or a screening interval of 2 yr instead of 4 yr is unlikely to explain the larger mortality reduction achieved in Sweden compared with Finland.
RCT Entities:
BACKGROUND: The European Randomised Study of Screening for Prostate Cancer trial has shown a 21% reduction in prostate cancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr interval and higher PSA cut-off. OBJECTIVE: To evaluate the impact of screening interval and PSA cut-off on PC detection and mortality. DESIGN, SETTING, AND PARTICIPANTS: We analysed the core age groups (55-69 yr at entry) of the Finnish (N=31 866) and Swedish (N=5901) screening arms at 13 yr and 16 yr of follow-up. Sweden used a screening interval of 2 yr and a PSA cut-off of 3.0ng/ml, while in Finland the screening interval was 4 yr and the PSA cut-off 4.0ng/ml (or PSA 3.0-3.9ng/ml with free PSA<16%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We compared PC detection rate and PC mortality between the Finnish and Swedish centres and estimated the impact of different screening protocols. RESULTS AND LIMITATIONS: If the Swedish screening protocol had been followed in Finland, 122 additional PC cases would have been diagnosed at screening, 84% of which would have been low-risk cancers, and four leading to PC death. In contrast, if a lower PSA threshold had been applied in Finland, at least 127 additional PC would have been found, with 19 PC deaths. CONCLUSIONS: The small number of deaths among cases that would have been potentially detectable in Finland with the Swedish protocol (or those that would have been missed in Sweden with the Finnish approach) is unlikely to explain the differences in mortality in this long of a follow-up. PATIENT SUMMARY: A prostate-specific antigen threshold of 3ng/ml versus 4ng/ml or a screening interval of 2 yr instead of 4 yr is unlikely to explain the larger mortality reduction achieved in Sweden compared with Finland.
Authors: Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja Journal: Lancet Oncol Date: 2010-07-02 Impact factor: 41.316
Authors: Lasse Saarimäki; Teuvo L Tammela; Liisa Määttänen; Kimmo Taari; Paula M Kujala; Jani Raitanen; Anssi Auvinen Journal: Int J Cancer Date: 2014-10-10 Impact factor: 7.396
Authors: Tuomas P Kilpeläinen; Dimitri Pogodin-Hannolainen; Kimmo Kemppainen; Kirsi Talala; Jani Raitanen; Kimmo Taari; Paula Kujala; Teuvo L J Tammela; Anssi Auvinen Journal: J Urol Date: 2017-01-16 Impact factor: 7.450
Authors: Anssi Auvinen; Sue M Moss; Teuvo L J Tammela; Kimmo Taari; Monique J Roobol; Fritz H Schröder; Chris H Bangma; Sigrid Carlsson; Gunnar Aus; Marco Zappa; Donella Puliti; Louis J Denis; Vera Nelen; Maciej Kwiatkowski; Marco Randazzo; Alvaro Paez; Marcos Lujan; Jonas Hugosson Journal: Clin Cancer Res Date: 2015-08-19 Impact factor: 12.531
Authors: Tuomas P Kilpeläinen; Teuvo L Tammela; Nea Malila; Matti Hakama; Henrikki Santti; Liisa Määttänen; Ulf-Håkan Stenman; Paula Kujala; Anssi Auvinen Journal: J Natl Cancer Inst Date: 2013-03-11 Impact factor: 13.506
Authors: Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Marco Zappa; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Liisa Määttänen; Hans Lilja; Louis J Denis; Franz Recker; Alvaro Paez; Chris H Bangma; Sigrid Carlsson; Donella Puliti; Arnauld Villers; Xavier Rebillard; Matti Hakama; Ulf-Hakan Stenman; Paula Kujala; Kimmo Taari; Gunnar Aus; Andreas Huber; Theo H van der Kwast; Ron H N van Schaik; Harry J de Koning; Sue M Moss; Anssi Auvinen Journal: Lancet Date: 2014-08-06 Impact factor: 79.321
Authors: Monique J Roobol; Ries Kranse; Chris H Bangma; Arno G J L H van Leenders; Bert G Blijenberg; Ron H N van Schaik; Wim J Kirkels; Suzie J Otto; Theo H van der Kwast; Harry J de Koning; Fritz H Schröder Journal: Eur Urol Date: 2013-05-25 Impact factor: 20.096
Authors: Thorgerdur Palsdottir; Tobias Nordstrom; Andreas Karlsson; Henrik Grönberg; Mark Clements; Martin Eklund Journal: BMJ Open Date: 2019-03-30 Impact factor: 2.692